Monday , November 20 2017
Home / Letter From The Editor / Editor’s Note, SGLT-2 Inhibitor Special Edition, March 2015

Editor’s Note, SGLT-2 Inhibitor Special Edition, March 2015

It has been two years since the first SGLT-2 inhibitor, canaglifozin, was approved by the FDA. Since that approval, two more drugs in this class have been approved and the acceptance and use by medical professionals has widened. The mechanism of this class is unique as it works directly on the elimination of extra glucose and seems to be regulated by glucose levels. This means that the odds of hypoglycemia are greatly reduced. This class is also unique in the manufacturers’ desire to get formulary coverage as all three of them are offering up to two years of free medication for insured patients.

To start off the new year we have the best of last year’s information, slides, and articles. Plus, we also have a simple but effective feature article to explain this class of drugs to your patients.